Medicus Pharma Ltd., a biotech company based in the US, has received the FDA's acceptance of its Type C meeting request.
1 report, 1 independent
Updated Aug 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medicus Pharma Ltd., a biotech company based in the US, has received the FDA's acceptance of its Type C meeting request.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Andrew Smith was appointed Chief Operating Officer of Medicus Pharma Ltd. on June 23, 2025.Sub-event
FDA accepted Type C meeting request from US-based biotech Medicus Pharma Ltd.1 source
Keep exploring
The entities involved
Related events
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
- FDA approval enables commercial opportunity involving CBRE Group.
- A product was launched in the U.S. market following FDA involvement.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- The FDA is monitoring product safety and manufacturing standards for Medisca Inc.
Coverage
Newest first; wire copies grouped- NewsfileMedicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Secon